Article Dans Une Revue Frontiers in Pharmacology Année : 2024

The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline

Michele Fusaroli
  • Fonction : Auteur
Charles Khouri
  • Fonction : Auteur
Emanuel Raschi
  • Fonction : Auteur

Résumé

Disproportionality analyses are the most-commonly used study design used in the post-marketing phase to detect suspected adverse drug reactions in individual case safety reports. Recent years have witnessed an exponential increase in published articles on disproportionality analyses, thanks to publicly accessible databases. Unfortunately, this trend was accompanied by concerns on lack of transparency and misinterpretation of results, both generating unjustified alarm and diluting true signals into overwhelming noise. The READUS-PV guideline for reporting disproportionality analysis was developed to tackle this emerging issue. In this perspective article, we describe the rationale behind the development of the READUS-PV guideline, the first collaborative initiative to harmonize the reporting of disproportionality analyses. The adoption of the checklists will assist researchers, regulators, and reviewers in the reporting, assessment, and publication of disproportionality analyses. Acknowledging the challenges ahead of effective implementation, we advocate for a global endorsement by Pharmacology Journals. A wide dissemination of the READUS-PV guideline is crucial to foster transparency and reproducibility of pharmacovigilance research, supporting an effective exploitation of disproportionality analysis among other irreplaceable post-marketing research tools to ensure drug safety.
Fichier principal
Vignette du fichier
BPH_FrontPharmacol_2024_Fusaroli.pdf (744) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04920784 , version 1 (30-01-2025)

Licence

Identifiants

Citer

Michele Fusaroli, Francesco Salvo, Charles Khouri, Emanuel Raschi. The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline. Frontiers in Pharmacology, 2024, 15, pp.1488725. ⟨10.3389/fphar.2024.1488725⟩. ⟨hal-04920784⟩

Collections

GENCI U1219
0 Consultations
0 Téléchargements

Altmetric

Partager

More